The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

With cases of measles—a highly contagious virus—popping up across the country, you might be wondering if you need another ...

As public health officials monitor a rise in U.S. measles cases, some may be wondering if they need a booster vaccine to ...

The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.

Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down ...

The pandemic death total stands at 1,252 as of February 1, 2025 (the most recent data available). The 5 reported deaths last ...

Follow the latest COVID-19 Vaccine news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to COVID-19 Vaccine notifications.